Fludarabine, cyclophosphamide and rituximab up to four courses as first line treatment for indolent non-hodgkin lymphomas

被引：0
|
作者：
Falantes, J. F. [1 ]
Ríos Herranz, E. [1 ]
Marin Niebla, A. [1 ]
Martino Galiana, M. L. [1 ]
Parody, R. [1 ]
Blas Orlando, J. M. [1 ]
机构：
[1] Hosp Univ Virgen Rocio, Seville, Spain
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1094
引用
收藏
页码：403 / 403
页数：1
相关论文
共 50 条
  • [21] Management of histologically indolent non-Hodgkin's lymphomas
    SolalCeligny, P
    BAILLIERES CLINICAL HAEMATOLOGY, 1996, 9 (04): : 669 - 687
  • [22] Clinical experience with fludarabine in indolent non-Hodgkin's lymphoma
    Zinzani, PL
    HEMATOLOGY JOURNAL, 2004, 5 : S38 - S49
  • [23] Pixantrone Dimaleate in Combination With Fludarabine, Dexamethasone, and Rituximab in Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
    Srokowski, Tomasz P.
    Liebmann, James E.
    Modiano, Manuel R.
    Cohen, Gary I.
    Pro, Barbara
    Romaguera, Jorge E.
    Kuepfer, Christine
    Singer, Jack W.
    Fayad, Luis E.
    CANCER, 2011, 117 (22) : 5067 - 5073
  • [24] STUDY OF GENE POLYMORPHISMS AS PREDICTORS OF TREATMENT EFFICACY AND TOXICITY IN PATIENTS WITH INDOLENT NON-HODGKIN LYMPHOMAS RECEIVING BENDAMUSTINE AND RITUXIMAB
    Cencini, E.
    Sicuranza, A.
    Fabbri, A.
    Raspadori, D.
    Bocchia, M.
    HAEMATOLOGICA, 2017, 102 : 109 - 109
  • [25] STUDY OF GENE POLYMORPHISMS AS PREDICTORS OF TREATMENT EFFICACY AND TOXICITY IN PATIENTS WITH INDOLENT NON-HODGKIN LYMPHOMAS RECEIVING BENDAMUSTINE AND RITUXIMAB
    Cencini, E.
    Sicuranza, A.
    Fabbri, A.
    Raspadori, D.
    Bocchia, M.
    HAEMATOLOGICA, 2016, 101 : S85 - S85
  • [26] Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas
    Minson, Adrian
    Tam, Constantine
    Dickinson, Michael
    Seymour, John F.
    CANCERS, 2022, 14 (05)
  • [27] Effective treatment of indolent non-Hodgkin's lymphomas with mitoxantrone, chlorambucil and prednisone
    Wöhrer, S
    Raderer, M
    Kaufmann, H
    Hejna, M
    Chott, A
    Zielinski, CC
    Drach, J
    ONKOLOGIE, 2005, 28 (02): : 73 - 78
  • [28] COST-EFFECTIVENESS ANALYSIS OF BENDAMUSTINE-RITUXIMAB TREATMENT COMPARED WITH FLUDARABINE-RITUXIMAB TREATMENT, IN PATIENTS WITH INDOLENT NON-HODGKIN'S LYMPHOMA IN PANAMA
    Desanvicente-Celis, Z.
    Obando, C. A.
    Rodriguez, E.
    Gonzalez, L.
    Muschett, D.
    VALUE IN HEALTH, 2014, 17 (03) : A83 - A83
  • [29] Immune Reconstitution Following Infusion of Autologous Blinatumomab Expanded T-Cells (BET) in CD20+Indolent Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia Receiving Front-Line Treatment with Fludarabine-Cyclophosphamide-Rituximab or Bendamustine-Rituximab
    Gritti, Giuseppe
    Lussana, Federico
    Ferrari, Silvia
    Barbui, Anna Maria
    Landi, Francesco
    Quaresmini, Giulia
    Borleri, Gianmaria
    Paganessi, Muriel
    Pavoni, Chiara
    Gotti, Elisa
    Capelli, Chiara
    Golay, Josee
    Introna, Martino
    Rambaldi, Alessandro
    BLOOD, 2022, 140 : 10325 - 10326
  • [30] EFFICACY AND SAFETY OF BENDAMUSTINE IN ASSOCIATION WITH RITUXIMAB AS FIRST-LINE TREATMENT FOR PATIENTS WITH INDOLENT NON-HODGKIN LYMPHOMA OR MANTLE CELL LYMPHOMA
    Cencini, E.
    Fabbri, A.
    Iannuzzi, A.
    Schiattone, L.
    Brambilla, C. Zuanelli
    Bocchia, M.
    HAEMATOLOGICA, 2017, 102 : 112 - 112
12345